aters ACQUITY UltraPerformance LC(R) System (UPLC(R)), a tandem quadrupole (TQ) mass detector, ACQUITY BEH analytical columns, all operated under Waters MassLynx(TM) 4.1 Mass Spectrometry Software. The MassLynx Software includes TargetLynx(TM) software for targeted analyte quantification and the QuanOptimise(TM) feature for automated system optimization and method development. This UPLC/MS/MS system operates with 1.7 micron ACQUITY BEH Columns and is a true UPLC system for measuring concentrations of veterinary drug residues, pesticides, and other contaminants in foods and beverages.
For More Information
More information on Waters ACQUITY TQD System, visit www.waters.com/tqd. For more information on Waters entire portfolio of LC/MS/MS products, please visit: http://www.waters.com/ms.
About Waters Corporation
Waters Corporation creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.
Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.
Waters, UltraPerformance LC, UPLC, ACQUITY, MassLynx, QuanOptimise, and TargetLynx are trademarks of Waters Corporation.
Brian J. Murphy
Public Relations Manager
Page: 1 2 3 Related biology technology :1
. KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure2
. Winning University of Melbourne Ph.D. research boosts the search for sensitive sensors3
. New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture4
. On the boil: New nano technique significantly boosts boiling efficiency5
. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management6
. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections7
. New Scandinavian collaboration boosts nanotech development8
. Murad Boosts Skin Immunity With the New Murad(R) Professional Line9
. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System10
. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer11
. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750